QT VASCULAR UPDATE ON MANUFACTURING TRANSFER

SINGAPORE, 4 September 2017 – QT Vascular Ltd., (the "**Company**" or "**QT Vascular**", and together with its subsidiaries, the "**Group**"), is a global company engaged in the design, assembly and distribution of advanced therapeutic solutions for the minimally invasive treatment of vascular disease. Further to the Company's circular dated 18 May 2017 ("**Circular**") and shareholders' approval obtained on 2 June 2017 for the potential transaction involving the disposal of certain assets of the Group relating to the uncoated peripheral products, i.e. Chocolate® PTA, the Board of Directors of the Company is pleased to provide an update on the asset purchase option agreement ("**Option Agreement**") with Medtronic, Inc. ("**Medtronic**").

The Company announced today that it has substantially completed the manufacturing transfer of its Chocolate® PTA product to Emerald Apex Pte Ltd, a third-party contract manufacturer, in Singapore. The Company expects that in the coming weeks, the necessary documentation will be verified and the transfer will be deemed completed. Completion of this manufacturing transfer will satisfy the requirement for one of the option triggers set out in the Option Agreement which allows Medtronic the right to exercise its option to purchase Chocolate® PTA ("**Option**") ("**First Option Trigger**").

"The manufacturing transfer supports cost reduction and higher volume manufacturing", stated Eitan Konstantino, PhD, CEO of QT Vascular. "It is also one of the three independent triggers of the Medtronic option listed in our previous announcement on 12 May 2017 and the Circular."

Further updates will be announced by the Company as and when there are any material developments, including the completion of the work related to the First Option Trigger or otherwise.

~~ End ~~

ABOUT QT VASCULAR LTD. (SGX Stock code: 5I0)

QT Vascular Ltd. together with its subsidiaries ("**QT Vascular**" or the "**Group**"), is an emerging leader in the development and commercialization of next generation minimally invasive products for the treatment of complex vascular disease. QT Vascular works closely with leading physicians and scientists from around the world to create differentiated devices that improve procedural and clinical outcomes.

For more information, please visit the Company's website at www.qtvascular.com

For media and analysts, please contact:

Mr Wayne Koo	(M): +65 9338 8166	wayne.koo@waterbrooks.com.sg
Ms Lynette Tan	(M): +65 9687 2023	lynette@waterbrooks.com.sg

Cautionary Note on Forward-Looking Statements

All statements other than statements of historical facts included in this announcement are or may be forward-looking statements. Forward-looking statements include but are not limited to those using words such as "expect", "anticipate", "believe", "estimate", "intend", "project", "plan", "strategy", "forecast" and similar expressions or future or conditional verbs such as "if", "will", "would", "should", "could", "may" and "might". These statements reflect the Company's current expectations, beliefs, hopes, intentions or strategies regarding the future and assumptions in light of currently available information. Such forward-looking statements are not guarantees of future performance or events and involve known and unknown risks and uncertainties. Accordingly, actual results may differ materially from those described in such forward-looking statements. Shareholders should not place undue reliance on such forward-looking statements, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements, subject to compliance with all applicable laws and regulations and/or the rules of the SGX-ST and/or any other regulatory or supervisory body or agency.

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"), for compliance with the Singapore Exchange Securities Trading Limited ("**SGX-ST**") Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this press release.*

This press release has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this press release including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship (Mailing Address: 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318 and E-mail: sponsorship@ppcf.com.sg).